The SWENOTECA group: A good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway

References

• Kvammen Ø MT, Solberg A, Møller B, Klepp OH, Fosså S, Tandstad T. Long-term relative survival after testicular cancer. In press 2015.
   Google Scholar
• Cancer Registry of Norway. Cancer in Norway 2012 – cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway. 2014. Available from http://www.kreftregisteret.no/Global/Cancer%20in%20Norway/2012/CIN_2012.pdf.
   Google Scholar
• Socialstyrelsen. Cancerincidens i Sverige 2013. Socialstyrelsen. 2014. Available from http://www.socialstyrelsen.se/publikationer2014/2014-12-10.
   Google Scholar
• Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish–Norwegian Testicular Cancer Group. J Clin Oncol 1990;8:509–18.
   PubMed Web of Science ®Google Scholar
• Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, et al. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish–Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1990;1:281–8.
   PubMed Web of Science ®Google Scholar
• Klepp O, Olsson AM, Ous S, Nilsson S, Hoisaether PA, Tveter K. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project. Scand J Urol Nephrol 1991;25:179–90.
   PubMed Web of Science ®Google Scholar
• Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9:818–26.
   PubMed Web of Science ®Google Scholar
• Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435–40.
   PubMed Web of Science ®Google Scholar
• Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, et al. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997;33:1038–44.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, et al. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol 2010;21:1858–63.
   PubMed Web of Science ®Google Scholar
• Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Stahl O, Klepp O, et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish–Norwegian Testicular Cancer Group. J Clin Oncol 2011;29:2032–9.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Stahl E, et al. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer – a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncol 2012;51:168–76.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer study group. J Clin Oncol 2011;29:719–25.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009;27:2122–8.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, et al. One Course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 2014;25:2167–72.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Cavallin-Stahl E, Dahl O, Haugnes HS, Langberg C, Laurell A, et al. Management of clinical stage I seminomatous testicular cancer: a report from SWENOTECA. J Clin Oncol 2014;32(Suppl):abstr 4508.
   Google Scholar
• Skoogh J, Steineck G, Stierner U, Cavallin-Stahl E, Wilderang U, Wallin A, et al. Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish population-based study 3–26 years after treatment. Acta Oncol 2012;51:185–97.
   PubMed Web of Science ®Google Scholar
• Skoogh J, Steineck G, Cavallin-Stahl E, Wilderang U, Hakansson UK, Johansson B, et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. Int J Androl 2011;34:183–92.
   PubMed Web of Science ®Google Scholar
• Skoogh J, Steineck G, Johansson B, Wildeang U, Stierner U; SWENOTECA. Psychological needs when diagnosed with testicular cancer: findings from a population-based study with long-term follow-up. BJU Int 2013;111:1287–93.
   PubMed Web of Science ®Google Scholar
• Klepp O. Nonseminomatous germ cell testis cancer: therapeutic outcome and prognostic factors. Trondheim: NTNU; 1991.
   Google Scholar
• Tandstad T. Vox populi, population-based outcome studies in testicular cancer. Trondheim: NTNU; 2011.
   Google Scholar
• Aass N. Malignant germ cell tumours: survival and side effects. Oslo: University of Oslo; 1991.
   Google Scholar
• Tandstad T, Solberg A, Hakansson U, Stahl O, Haugnes HS, Oldenburg J, et al. Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. Acta Oncol 2015;54:493–9.
   PubMed Web of Science ®Google Scholar
• Kier MG, Lauritsen J, Almstrup K, Mortensen MS, Toft BG, Rajpert-De Meyts E, et al. Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based study. Ann Oncol 2015;26:737–42.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Cavallin-Stahl E, Dahl O, Haugnes HS, Langberg CW, Laurell A, et al. One course of adjuvant BEP in clinical stage I, nonseminoma: mature and expanded results from the SWENOTECA group. ASCO Meeting Abstracts 2013;31:4553.
   Google Scholar
• Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol 2014;65:1095–106.
   PubMed Web of Science ®Google Scholar
• Nichols CR, Kollmannsberger C. Vox populi: using community-based studies to determine best management of early-stage nonseminoma. J Clin Oncol 2009;27:2114–16.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Pagliaro L, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: results of GETUG 13. J Clin Oncol 2013;31(Suppl):abstr LBA4500.
   Google Scholar
• Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007;25:247–56.
   PubMed Web of Science ®Google Scholar
• Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448–52.
   PubMed Web of Science ®Google Scholar